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Abstract
Background: Weight-loss medicines, including crude drugs and herbal supplements disguised as diet-aid products,
are readily obtainable and distributed widely, especially in Southeast Asia. Even if such products are unapproved or
prescription-only medicines, consumers can purchase them through an agency or directly on the Internet. We
evaluated the quality and safety of herbal products purchased on the Internet to reveal their influence on public
health.
Methods: Diet-aid products containing Bukuryo (Poria sclerotium), Bakumondo (Ophiopogonis tuber), or Daio
(rhubarb rhizome) were purchased through websites that did not provide physical addresses or which advertised
misleading medicines (e.g., unapproved Cialis 100 mg tablets, Viagra 100 mg tablets) on websites. We carefully
noted details in the descriptions on package inserts or accompanying product characteristics and analyzed the
ingredients using qualitative and quantitative methods, namely high-performance liquid chromatography equipped
with a photodiode array detector. We requested the respective manufacturers to authenticate their products
through a structured questionnaire.
Results: We purchased 15 items from 15 Internet sites and imported all 15 items to Japan. One item stated to
contain rhubarb rhizome was identified as a prescription medicine; the others were dietary supplements and not
medicines. Even though we did not analyze the constituents of all crude drugs, we found some active ingredients
in the items. Sibutramine was detected in items confirmed to be supplements, including those containing Poria
sclerotium and Ophiopogonis tuber. Each capsule contained ≈ 12 mg of sibutramine, which is the daily dose for
anti-obesity medicines. Sibutramine is not approved for use in Japan and its sale has been suspended in Europe
and the USA owing to serious adverse effects on the circulatory system.
Conclusions: Our findings indicate that dietary supplements containing injurious ingredients are distributed to
Japanese consumers and potentially to a broader international audience, and that purchasing them through
unreliable websites bears potential health risks. To avoid potential adverse events, there should be adequate alerts
about the risks of taking products without appropriate indications.
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Background
The increasing international trade in pharmaceuticals
via sales on the Internet has facilitated the entry of
counterfeit products into the supply chain. Counterfeit
products include products with ingredients different
from those labeled or advertised, without active ingredi-
ents, with insufficient or excessive active ingredients,
and with misleading packaging [1]. Since 2011, the
World Health Organization (WHO) has suggested that
counterfeit medicines be termed “spurious/falsely la-
belled/falsified/counterfeit” (SFFC) medicines [2]. In par-
allel, Attran and colleagues recommended reserving the
term “falsified” for crimes against public health [3]. They
defined “falsified medicines” as medicines that violate
the quality specifications of the regulator—but what
truly defines and distinguishes them is criminal intent
[3]. Use of such medicines can result in treatment failure
or even death. The WHO has warned that medicines
purchased over the Internet from sites that conceal their
physical addresses are falsified in >50 % of cases [1]. An
individual can import restricted quantities of medication
for personal use without undergoing special procedures
in Japan [4]. Accordingly, pharmaceutical regulatory au-
thorities in many countries and regions such as the Min-
istry of Health, Labour and Welfare in Japan [5], the US
Food and Drug Administration [6, 7], European Medi-
cines Agency [8], Medicines and Healthcare Products
Regulatory Agency in the United Kingdom [9, 10],
Health Canada [11], and the Therapeutic Goods Admin-
istration in Australia [12], promote awareness regarding
medicines that should be avoided and not purchased
over the Internet.
Obtaining accurate information on the extent of falsi-
fied medicines is difficult because the falsified medicines
detected are a small proportion of the total number of
falsified medicines that are available. Because of this
situation, sharing information and promoting awareness
in regard to falsified medicines may help to combat the
health hazards associated with the use of falsified medi-
cines. Preventing health hazards is a societal require-
ment. It is necessary to avert the serious adverse effects
of imported medicines by undertaking countermeasures
supported by field-based and scientific evidence. Our
research team has highlighted the public-health implica-
tions of privately importing medicines such as levonor-
gestrel and piracetam (which are prescription medicines
in Japan) [13, 14].
Among privately imported medicines in Japan, anti-
obesity medicines are the most popular, followed by
medicines for erectile dysfunction and hair growth [15].
Reductil® contains sibutramine, and is one of the most
popular anti-obesity agents found on websites, but it is
not approved in Japan. In one Reductil-containing prod-
uct imported via the Internet, the maximum dose of
sibutramine described in the explanatory note in Japa-
nese was nearly three-times the dose described in the
true package insert, but this item was confirmed as “au-
thentic” by the manufacturer [14]. In 2012, it was re-
ported that a product labeled Xenical® (120 mg orlistat),
a synthetic anti-obesity medicine imported via the Inter-
net, had no active ingredient except starch. Furthermore,
it was a falsified medicine according to the response
from the manufacturer to our requests for authentica-
tion [16].
In the present study, we investigated the quality of
samples of diet-aid products and weight-loss medicines
purchased on the Internet using chemical analyses.
Methods
Sample collection
Using Japanese keywords for “personal import agent”,
“slimming” and “obesity” (terms used in a list of “plant-
origin materials used mainly as pharmaceutical medi-
cine” created by the Ministry of Health, Labour and
Welfare in Japan [17]), we searched for diet-aid products
that were described on Internet sites as containing
Bukuryo (Poria, Poria sclerotium), Bakumondo (Ophio-
pogonis tuber), or Daio (rhubarb rhizome) on the Japa-
nese Google search engine (www.google.co.jp). Among
the websites advertising such products, we selected those
sellers that did not disclose their physical addresses and
those that advertised the sale of falsified medicines (e.g.,
with unapproved dosages) in August 2009 to purchase
the items mentioned above [16]. Poria, Ophiopogonis
tuber and rhubarb have been approved for reimburse-
ment under Japanese national health insurance as pre-
scription and over-the-counter medicines. These crude
drugs are used widely as diuretics or purging agents in
Japan.
Observation
We carefully noted the descriptions (ingredients, quan-
tity, dosage form, package presentation, usage instruc-
tions, safety information, manufacture date, expiration
date, batch number, name and address of the manufac-
turer) on the website and package insert or the summary
of product characteristics of the items purchased.
Authenticity investigation
The methodology of the authenticity investigation and
registration verification was adopted from that provided
by the WHO [16, 18]. We requested the respective
manufacturers to authenticate their products through a
structured questionnaire (including verification of the
descriptions on the package, equivalence in appear-
ance, and licensed status for manufacturing and mar-
keting) sent by post together with a part or photograph
of the items.
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Materials
We purchased benfluorex, orlistat, and aristolochic acid
(mixture of I and II) from Sigma–Aldrich Co. LLC (Saint
Louis, MO, USA). Lovastatin was purchased from To-
ronto Research Chemicals (Toronto, ON, Canada). We
bought rimonabant from Cayman Chemical Company
(Ann Arbor, MI, USA), and sibutramine hydrochloride
from Tocris Bioscience (Minneapolis, MN, USA). We
purchased fenfluramine and N-nitroso-fenfluramine
from Wako Pure Chemical Industries, Ltd. (Osaka,
Japan). These compounds were the reference standards
of the compounds that were not listed on the package or
insert. To verify that rhubarb rhizome was present, sen-
noside A (one of the anthraquinone glycosides in rhu-
barb and a compound used for identification of rhubarb
rhizome according to the Japanese Pharmacopoeia 16)
and authentic rhubarb rhizome were purchased from
Nacalai Tesque, Inc. (Kyoto, Japan) and Tochimoto Ten-
kaido Co., Ltd. (Osaka, Japan), respectively. The refer-
ence standards of the other anthraquinone glycosides,
aloe-emodin and emodin were purchased, respectively,
from Toronto Research Chemicals and Tokyo Chemical
Industry Co., Ltd. (Tokyo, Japan). Rhein and chrysophanol
were bought from Extrasynthese S.A. (Genay, France).
High-performance liquid chromatography (HPLC)-grade
reagents of acetonitrile, 2-propanol, methanol, and tri-
fluoroacetic acid were purchased from Wako Pure Chem-
ical Industries, Ltd. All other chemicals were available
commercially and of analytic grade. A membrane filter
(Millex®-LG; pore size, 0.20 μm; Merck Millipore, Billerica,
MA, USA) was used for filtration treatment for HPLC
analyses. Thin-layer chromatography (TLC; silica gel
60 F254; 20 × 20 cm, Merck, Billerica, MA, USA) was
employed for analyses.
Sample preparation
We categorized purchased materials into three types of
dosage form: soft capsules, hard capsules, and sugar-
coated tablets. For soft capsule samples, we cut the cap-
sules open, weighed the contents, transferred them to a
100-mL volumetric flask, and added an appropriate
quantity of mobile phase. This solution was mixed by
shaking for 90 s, passed through a membrane filter and
analyzed. For hard capsule samples, we weighed the con-
tent in the capsule, which was sonicated with ≈ 80 mL of
methanol for 30 min and diluted to 100 mL in a volu-
metric flask. The diluent was passed through a mem-
brane filter and analyzed. For the sugarcoated tablet
sample, we removed the coating with water. Thereafter,
the whole of the uncoated tablet was sonicated with ≈
80 mL of methanol for 30 min and diluted to 100 mL in
a volumetric flask. The diluent was passed through a
membrane filter and analyzed.
We dissolved each of the reference standards of sen-
noside A, aloe-emodin, chrysophanol, emodin, and rhein
(1 mg) in 10 mL of ethanol. We passed each solution
through a membrane filter and analyzed them.
To extract rhubarb rhizome, we pulverized adequate
amounts of rhubarb rhizome. To 1 g of pulverized rhu-
barb rhizome, we added 10 mL of ethanol and then soni-
cated it for 10 min (2510 J-MF; Branson Ultrasonic
Corporation, Danbury, CT, USA), and centrifuged it for
5 min (800 × g). The supernatant was passed through a
membrane filter and analyzed using TLC.
To 200 mg of pulverized rhubarb rhizome, we added
4 mL of ethanol, sonicated it for 10 min, and centrifuged
it for 5 min (800 × g). A diluent of 1 mL of supernatant
with 3 mL of ethanol was filtered and injected into the
HPLC system.
HPLC analyses
The three HPLC methods described below were employed
to detected benfluorex, lovastatin, rimonabant, sibutra-
mine hydrochloride, orlistat, aloe-emodin, chrysophanol,
emodin, rhein, aristolochic acid, fenfluramine, and N-
nitroso-fenfluramine. To identify the compounds con-
tained in purchased items, we confirmed that a single
peak appeared upon simultaneous injection with the refer-
ence standard of the substance.
System suitability
HPLC was undertaken according to the method de-
scribed in the Japanese Pharmacopoeia 16 [19]. Each
product was analyzed before the expiry date detailed on
the label.
Method 1
Benfluorex, rimonabant, sibutramine hydrochloride and
orlistat are well known synthetic anti-obesity com-
pounds. Lovastatin is a cholesterol-lowering statin and
has often been mistaken for having anti-obesity effects.
We carried out quantitative determination of benfluorex,
lovastatin, rimonabant, sibutramine hydrochloride, and
orlistat with the calibration curves constructed for a
HPLC system equipped with a photodiode array (PDA)
detector (LC-20 AD; Shimadzu, Kyoto, Japan) according
to the method for chemical analyses described in our
previous study [16]. The analytical column was a Might-
ysil RP-18GP (4.6 × 150 mm, 5 μm; Kanto Chemical Co.,
Inc., Tokyo, Japan). The column temperature was main-
tained at 45 °C using a column oven (CTO-20A;
Shimadzu). The mobile phase was a mixture of methanol
and 0.02 mol/L phosphate buffer, pH 7.0, (17:3, v/v). The
flow rate was 1.2 mL/min. The detection wavelength
was 225 nm and we recorded ultraviolet (UV) spectra at
200–400 nm (SPD-M20A; Shimadzu). The injection vol-
ume was 20 μL. Under these conditions, benfluorex,
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1 A 韓国痩身1号(美体型) 西安華威保健有限公司 China Supplement 山楂 (Crataegi fructus),茯苓 (Poria sclerotium),
菜菔子 (Raphani semen)
No No
2 B 終極痩身 西安華威保健有限公司 China Supplement 蘭姫花,櫻花素,錦帯花,珍珠粉 (pearl powder),
蘆薈 (aloe),核桃油 (walnut oil)
No No
3 C 韓国痩身1号(美腿型) 西安華威保健有限公司 China Supplement 茯苓 (Poria sclerotium),菜菔子 (Raphani semen),
苦宁素
No No
4 D 韓国痩身1号(収腹提臀型) 西安華威保健有限公司 China Supplement 山楂 (Crataegi fructus Fructus), 香茶素, 决明子
(Cassiae semen), 荷叶素
No No
5 B 終極痩身 西安華威保健有限公司 China Supplement 蘭姫花,櫻花素, 錦帯花, 珍珠粉 (pearl powder),









西安華威保健有限公司 China Supplement 山楂 (Crataegi fructus Fructus), 香茶素, 决明子
(Cassiae semen), 荷叶素
No No
8 G RELACORE America Leptin Phrmaceuticals
Limited
USA Supplement Not listed No No
9 H 代代花胶嚢 Kuming Dali Industry & Trade
Co., Ltd.
China Supplement 代代花 (Citrus aurantii flos) No Yes
10 I 妙姿 百年医葯集団有限公司 China Supplement 山楂 (Crataegi fructus Fructus), 蘆薈 (Aloe),枳実
(Aurantii Fructus immaturus),桃仁 (Persicae semen)
No No
11 J 韓国緑素抗脂胶嚢 珠海尚高乐实业发展有限公
司
China Supplement 奇昇果,茶叶,决明子 (Cassiae semen), 荷叶素,
山楂 (Crataegi fructus Fructus), 麦冬(Ophiopogonis
tuber),檳榔 (Areca semen),青皮 (Citrus unshiu
pericarpium immaturus)
No No
12 J 韓国緑素抗脂胶嚢 珠海尚高乐实业发展有限公
司
China Supplement 奇昇果,茶叶,决明子 (Cassiae semen), 荷叶素,
山楂 (Crataegi Fructus Fructus),麦冬(Ophiopogonis
tuber),檳榔 (Arecae semen),青皮 (Citrus unshiu
pericarpium immaturus)
No No
13 J 韓国緑素抗脂胶嚢 珠海尚高乐实业发展有限公
司
China Supplement 奇昇果,茶叶,决明子 (Cassiae Cassiae semen),
荷叶素,山楂 (Crataegi Fructus), 麦冬(Ophiopogonis
tuber),檳榔 (Arecae semen),青皮 (Citrus unshiu
pericarpium immaturus)
No No
14 K 軽身減肥片 陕西君寿堂制药有限公司 China Prescription
medicine
大黄 (rhubarb rhizome), 防已 (Sinomeni caulis
et rhizoma), 丹参 (Salviae Miltiorrhizae radix), 茵陜
(Artemisiae Capillaris herba),沢泻 (Alismatis rhizoma),
山楂 (Crataegi fructus Fructus),水牛角,淫羊藿
(Epimedii herba),黄芪 (Astragali radix),白朮
(Atractylodis rhizoma),川芎 (Cnidii rhizoma)
No No




















lovastatin, rimonabant, sibutramine hydrochloride, and
orlistat were eluted in that order and separated com-
pletely in the chromatogram (data not shown). The
standard ingredient was identified by its retention time
and absorption spectrum. To prepare solutions of stan-
dards, we dissolved benfluorex, lovastatin, rimonabant,
sibutramine hydrochloride, or orlistat with methanol and
diluted them stepwise to the appropriate concentration.
Method 2
We detected aloe-emodin, chrysophanol, emodin, and
rhein (the active ingredients of rhubarb rhizome) using
the HPLC-PDA system. The analytical column was as
described for Method 1. We maintained the column
temperature at 45 °C using a column oven (CTO-10Avp;
Shimadzu). For the mobile phase, we prepared a mixture
of methanol, acetonitrile, and 0.1 % formic acid (8:1:1, v/
v/v). The flow rate was 1.0 mL/min. We set the detec-
tion wavelength at 254 nm and recorded UV spectra at
200–400 nm (SPD-M10Avp; Shimadzu). The injection
volume was 10 μL.
Method 3
Aristolochic acid is a harmful compound found in Chin-
ese herbal supplements that promote anti-obesity and
which are imported via the Internet [20, 21]. Fenflur-
amine and N-nitroso-fenfluramine are also harmful
compounds which have anti-obesity effects similar to
those of sibutramine [22]. Chromatograms were re-
corded for the standard compounds of aristolochic acid,
fenfluramine, and N-nitroso-fenfluramine using the
HPLC-PDA system according to methods described in
the Japanese Pharmacopoeia 16 [19]. The analytical col-
umn was a Cosmosil C18-AR-II (4.6 × 150 mm, 5 μm;
Nacalai Tesque, Inc.). We maintained the column
temperature at 40 °C using a column oven (CTO-20 AC;
Shimadzu). The flow rate was 1.0 mL/min. We recorded
UV spectra at 200–400 nm (SPD-M10Avp; Shimadzu).
The injection volume was 10 μL.
To detect aristolochic acid, a mobile phase (methanol
and 0.02 M phosphate buffer at pH 7.0 (1:1, v/v)) was
prepared. We set the detection wavelength at 310 nm.
To detect fenfluramine and N-nitroso-fenfluramine, we
prepared a mobile phase (methanol and water (4:6, v/v))
to which we added, respectively, 1 mL of trifluoroacetic
acid and a mixture of methanol and 0.2 % trifluoroacetic
acid solution (3:2, v/v). We set the detection wavelength
at 210 nm.
TLC analyses
We detected the ingredients in the sugarcoated tablet
supposedly containing rhubarb rhizome and the extract
of authentic rhubarb rhizome with reference to the mono-
graph on rhubarb rhizome in the Japanese Pharmacopoeia
16 [19] and compared them. We developed a plate with a
mixture of 1-propanol, ethyl acetate, water, and acetic acid
(40:40:30:1, v/v/v/v) to ≈ 40 mm. We observed spots under
UV light at 254 nm (SLUV-6; 254/365 nm; As One,
Osaka, Japan).
Results
We purchased 15 items 11 products from six manufac-
turers sold on 15 Internet sites. Among the 15 websites,
five lacked a description of their physical addresses, and
four, one, and five sites advertised falsified Cialis, Levitra,
and Viagra, respectively. These falsified products had
unapproved content or dosage forms.
Of the 15 items, 11 items from eight products con-
tained Poria, three items from one product contained
Ophiopogonis tuber, and one item contained rhubarb
rhizome. One item containing rhubarb rhizome was
confirmed to be authentic and was a prescription medi-
cine according to the reply from the manufacturer; the
others were dietary supplements and not medicines. We
noted the crude-drug components of each item listed in
the descriptions on the outer packaging or package in-
serts (Table 1). For one item, no information about such
components was provided.
Items purchased from the 15 websites were sent by
nine dispatchers, including one whose shipping label was
indecipherable. All dispatchers were located in China. Of
the six manufacturers, one was located in the USA, and
the others were in China.
In the authenticity investigation, only one of the six
manufacturers replied: the item containing rhubarb rhi-
zome manufactured by the respondent was confirmed to
be a genuine product according to the manufacturer’s
reply. With three manufacturers, the questionnaires
were returned because the address was incomplete, or
the website provided on the outer packaging could not
be accessed. Two e-mail addresses of these three manu-
facturers were not deliverable.
We categorized the 15 items into three types of dosage
form: there were eight soft-capsule samples, six hard-
capsule samples, and one sugarcoated-tablet sample.
Fig. 1 Molecular structure of sibutramine
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Fig. 2 Chromatogram in HPLC analyses under Method 1. a Reference standard of sibutramine; b item number 1; c item number 10; and
d item number 14
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One soft-capsule sample could not be analyzed because
of an insufficient number of capsules. All soft-capsule
samples were filled with a clear, oily liquid. In the chro-
matogram of this fluid dissolved in the mobile phase for
HPLC analyses, we found that the analytic procedure
(Method 1) revealed a peak. The retention time of this
peak was ≈ 11 min, which is consistent with sibutramine
hydrochloride (Figs. 1, 2a, b). In addition to the reten-
tion time, the absorbance spectrum of this peak showed
close similarity to that of the reference standard of sibu-
tramine hydrochloride (Fig. 3a, b). No other isolated
peak was detected. All seven soft-capsule samples, which
were not described as containing sibutramine, showed
this characteristic chromatogram.
All hard-capsule samples had fawn- or tan-colored
granular contents, which contained plant fragments as
according to microscopic examination. After dissolving
these contents in methanol, HPLC Method 1 revealed a
peak at ≈ 11 min (Fig. 2c). The retention time and ab-
sorbance spectrum of this peak showed a close similarity
to that of the reference standard sibutramine hydro-
chloride (Figs. 2a, c, 3a, c). All six hard-capsule samples
showed this characteristic chromatogram. Other distinct
peaks of the crude drug components appeared over 1–
2.5 min.
After removing its coating, the one sugarcoated tablet
preparation (number 14) was found to have brown con-
tents. In the TLC analyses, sennoside A (the subject of
identification of rhubarb rhizome in the Japanese
Pharmacopoeia 16) was not detected in the extract of
this item, whereas the spot derived from sennoside A
appeared in the extract of rhubarb rhizome (data not
shown). In HPLC analyses under Method 1, some peaks
appeared at 1–5 min; no peak was detected at ≈ 11 min
in the chromatogram of this extract with methanol
(Fig. 2d); no peaks appeared after 5 min when analyses
were undertaken with the coating agents removed. The
diluent with methanol showed some peaks in the chro-
matogram under Method 2, and these peaks were con-
sistent with the pattern of extract of rhubarb rhizome
(Fig. 4a, b). The retention time and absorbance spectrum
of four of the five types of peaks (Fig. 5-1, 5-2, 5-3, 5-4,
5-5, 5a, b, c, d, e) showed a close similarity to those of
the reference standards of aloe-emodin (Figs. 4c, 5i),
rhein (Figs. 4d, 5-ii), emodin (Figs. 4e, 5-iii), and chryso-
phanol (Figs. 4f, 5-iv), but one of them was not known
(Figs. 4a, b, 5-5, 5e). The constituent of another peak




Fig. 3 Absorbance spectrum of the peaks that appeared in HPLC
analyses under Method 1. a Reference standard of sibutramine;
b the peak that appeared in HPLC analyses of item number 1;
and c the peak that appeared in HPLC analyses of item
number 10
Yoshida et al. BMC Complementary and Alternative Medicine  (2015) 15:430 Page 7 of 11
In HPLC analyses under Method 3, aristolochic acid,
fenfluramine, and N-nitroso-fenfluramine were not de-
tected in any item.
For items containing sibutramine, quantitative analyses
were carried out using the HPLC-UV method. The mean
quantity of sibutramine in each item was 12.37 ± 4.63 mg;
the minimum and maximum were ≈ 6 and ≈ 25 mg/cap-
sule, respectively (Table 2). In one item (number 8), the
quantity of sibutramine varied among capsules.
Discussion
We evaluated the quality of imported anti-obesity medi-
cines comprising crude drugs purchased via the Inter-
net. Anti-obesity medicines sold on the Internet include
synthetic medicines (e.g., sibutramine hydrochloride,
orlistat) as well as crude-drug products and supple-
ments, which are advertised as promoting weight loss.
One purchased item containing rhubarb rhizome was
identified as a prescription medicine in our authenticity
investigation and the others were advertised as dietary
supplements that were matched with package informa-
tion. After HPLC analyses, we determined that the main
ingredient of all soft- and hard-capsule samples was the
synthetic anti-obesity agent sibutramine (Figs. 2a, b, c,
3), but this information was not described on the pack-
age, package insert and/or the website except for one
item “代代花胶嚢 (item number 9)”. On the website ad-
vertising 代代花胶嚢, we found a description stating
that a weight-loss effect owing to sibutramine could be
expected (Table 1). Hence, the items confirmed to con-
tain sibutramine could be classified as “falsified prod-
ucts” according to the definition of Attran and
colleagues [3]. For the soft-capsule samples, only sibutra-
mine was detected and no crude drugs were found.
Among those 13 items, each capsule contained ≈ 12 mg
of sibutramine, which was equivalent to or exceeded the
recommended daily dose (10 mg) for an anti-obesity
medicine. One capsule contained 25 mg of sibutramine.
By contrast, the one sugarcoated tablet preparation did
not contain sibutramine hydrochloride, benfluorex, lova-
statin, rimonabant, or orlistat (Fig. 2d). The assayed
sample of the sugarcoated tablet was found to contain
quantities of the major constituents of indicated crude
drugs such as the anthraquinones (except for sennoside
A) in rhubarb rhizome; the plant fragments in the sam-
ple could not be identified (Figs. 4, 5).
Fig. 4 Chromatogram in HPLC analyses under Method 2. Item
number 14: an extract of rhubarb rhizome and reference standards of
anthraquinones in rhubarb rhizome were analyzed by HPLC under
Method 2. a, b, c, d, e, and f show, respectively, the chromatogram
of item number 14, and the extracts of rhubarb rhizome, aloe-
emodin, rhein, emodin, and chrysophanol
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These findings indicate that sibutramine was present
in most of the herbal supplements that we purchased
online and which we assayed. Even supplements that are
described as containing only crude drugs should be used
carefully because they might contain synthetic adulter-
ants. This is especially true for products purchased from
the Internet, for which there is often a lack of compliance
to national regulatory standards. Our results indicate that
the diet-aid products that we examined may exert an anti-
obesity effect as a result of the sibutramine, they contained
and not through the crude drugs themselves.
With regard to item number 15 (which could not be
evaluated because of an insufficient number of capsules),
we detected sibutramine in another item (number 3)
that had the same product name, lot number, date of
manufacture, and which was sent from the same
dispatcher. Thus, sibutramine may have been present in
that item.
Sibutramine products are not approved for use in
Japan, but they are among the most popular anti-obesity
agents sold on the Internet. Sibutramine is a serotonin
reuptake inhibitor and noradrenaline reuptake inhibitor,
and it induces weight loss through a combination of re-
duced appetite, feelings of satiety and, possibly, the in-
duction of thermogenesis [23, 24]. However, some
adverse cardiovascular events in patients treated with
sibutramine have been reported [25]. Following data ob-
tained from the Sibutramine Cardiovascular Outcomes
Trial, sibutramine was withdrawn from the market in
the USA, Canada, European Union and UK in 2010. The
Committee for Medicinal Products for Human Use in
the European Medicines Agency recommended that all
marketing authorization for medicines containing sibu-
tramine be suspended across the European Union [26–
30]. Weight-loss medicines such as herbal supplements
disguised as diet-aid products can be acquired readily on
the Internet. Some of those products may include harm-
ful substances (e.g., sibutramine), so medicines and sup-
plements purchased on the Internet can damage health.
Medicines may be categorized into two basic types:
synthetic medicines and herbal medicines compounded
from crude drugs. Often, herbal medicines and supple-
ments are purported to have a lower prevalence of ad-
verse effects than synthetic medicines. However, health
Fig. 5 Absorbance spectrum of the peaks that appeared in HPLC analyses under Method 2. The absorbance spectrum of five types of peaks
appeared in the chromatogram of item number 14 (1–5) and the extract of rhubarb rhizome (a–e); reference standards of aloe-emodin (i), rhein
(ii), emodin (iii), and chrysophanol (iv) are shown
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problems caused by Chinese herbal medicines containing
aristolochic acid have been reported [20, 21, 31, 32]. Since
2002, in Japan, over 700 people (mostly women) have de-
veloped health problems after taking unapproved Chinese
diet-aid products containing N-nitroso-fenfluramine [22].
In the present study, we found that herbal supplements
purchased on the Internet contained sibutramine (a
synthetic anti-obesity drug) but not aristolochic acid, fen-
fluramine, or N-nitroso-fenfluramine. These herbal sup-
plements may be regarded as falsified products because
they contained sibutramine, which was not listed as a
component.
Our findings indicate clearly that herbal products pur-
chased on the Internet carry the risk of adverse effects.
It is necessary to halt the increase in the number of indi-
viduals becoming ill after taking medicines purchased on
the Internet. Warnings need to be given about the care-
less use of products disguised as “weight-loss medicines”
sold over the Internet. Consumers need to become more
fully aware of the risks involved if they purchase such
products from the Internet.
Conclusions
Products confirmed to be supplements and which
underwent chemical analyses contained sibutramine,
which can exert adverse cardiovascular events. Herbal
products that contain harmful substances are distributed
worldwide and any individual can obtain them through
the Internet, even though the dangers of purchasing
medicines and/or supplements online have been docu-
mented [33, 34]. These products pose serious safety risks
[20–22, 35]. These fraudulent products should not be
sold on the Internet but, for the moment, consumers
should protect themselves by avoiding inappropriate use
of pharmaceutical agents. To expedite access to genuine
products for consumer safety, improved regulation of il-
legitimate medicines and supplements, increased inspec-
tion and guidance to comply with existing rules, and
international cooperation by public-health agencies, drug
regulatory bodies and law enforcement agencies could
help ensure secure pharmaceutical distribution. Govern-
ments and individual consumers need to be more vigi-
lant regarding the possible health risks associated with
use of these bogus herbal preparations.
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Table 2 Sibutramine quantities
Product number Type of dosage form Quantity (mg/unit) Authenticity Reason
1 Soft capsule 11.48 ± 0.61 Falsified (suspected) Mislabeled
2 Soft capsule 13.43 ± 0.81 Falsified (suspected) Mislabeled
3 Soft capsule 10.18 ± 1.63 Falsified (suspected) Mislabeled
4 Soft capsule 10.85 ± 0.25 Falsified (suspected) Mislabeled
5 Soft capsule 13.13 ± 0.41 Falsified (suspected) Mislabeled
6 Soft capsule 6.26 ± 2.14 Falsified (suspected) Mislabeled
7 Soft capsule 10.19 ± 8.52 Falsified (suspected) Mislabeled
8 Hard capsule 25.85 ± 1.43 Falsified (suspected) Mislabeled
9 Hard capsule 15.53 ± 1.91 Falsified (suspected) Mislabeled
10 Hard capsule 10.03 ± 0.97 Falsified (suspected) Mislabeled
11 Hard capsule 9.67 ± 0.41 Falsified (suspected) Mislabeled
12 Hard capsule 12.82 ± 1.02 Falsified (suspected) Mislabeled
13 Hard capsule 11.38 ± 0.17 Falsified (suspected) Mislabeled
14 Sugarcoated tablet Not detected Genuine The manufacturer did not or provide
results of chemical analyses
15 Soft capsule Not tested because of an
insufficient number of capsules
Unknown
The quantity of sibutramine is represented as the mean ± SD (n = 3)
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